Search results for "Pre- and post-test probability"

showing 7 items of 7 documents

Validation of the STA-Liatest DDi assay for exclusion of proximal deep vein thrombosis according to the latest Clinical and Laboratory Standards Inst…

2018

: Recommended strategy for venous thromboembolism (VTE) diagnosis includes the use of sensitive D-dimer (DDi) assays along with pretest probability (PTP) assessment. The Clinical and Laboratory Standards Institute (CLSI) recently issued a guideline (US FDA endorsed) on DDi in VTE exclusion. Such guideline specifies the ideal D-dimer assay characteristics and target population. Demonstrate STA-LiatestD-Di performance combined with a PTP score for proximal deep vein thrombosis (pDVT) exclusion in a CLSI compliant study. International, multicenter, prospective nonrandomized, noninterventional clinical outcome management study conducted in a standard-of-care setting. DDi was measured in DVT-sus…

AdultMalemedicine.medical_specialtyDeep veinShort Communications030204 cardiovascular system & hematologySensitivity and SpecificityFibrin Fibrinogen Degradation ProductsSTA-Liatest DDi03 medical and health sciences0302 clinical medicineInternal medicineOutpatientsD-dimermedicineHumansProspective StudiesProspective cohort studyexclusiondeep venous thrombosisAgedVenous ThrombosisUnited States Food and Drug Administrationbusiness.industryImmunoturbidimetryHematologyGeneral MedicineGuidelineMiddle Agedmedicine.diseaseThrombosisUnited StatesPulmonary embolismClinical trialPre- and post-test probabilitymedicine.anatomical_structureD-dimerFemalebusiness030215 immunologyBlood Coagulation & Fibrinolysis
researchProduct

Sex-related differences in D-dimer levels for venous thromboembolism screening.

2021

Background D-dimer is generally considered positive above 0.5 mg/L irrespective of sex. However, women have been shown to be more likely to have a positive D-dimer after controlling for other factors. Thus, differences may exist between males and females for using D-dimer as a marker of venous thromboembolic (VTE) disease. We hypothesized that the accuracy of D-dimer tests may be enhanced by using appropriate cutoff values that reflect sex-related differences in D-dimer levels. Methods This research is a secondary analysis of a multicenter, international, prospective, observational study of adult (18+ years) patients suspected of VTE, with low-to-intermediate pretest probability based on We…

AdultMalemedicine.medical_specialtyFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicineInternal medicineD-dimermedicineHumansProspective StudiesVenous ThrombosisReceiver operating characteristicbusiness.industry030208 emergency & critical care medicineGeneral MedicineVenous Thromboembolismmedicine.diseaseConfidence intervalPulmonary embolismPre- and post-test probabilityDeep vein thrombosis (DVT)CohortEmergency MedicineFemalebusinessPulmonary EmbolismLower limbs venous ultrasonographyAcademic emergency medicine : official journal of the Society for Academic Emergency MedicineREFERENCES
researchProduct

Deep Vein Thrombosis

2015

Venous thromboembolism (VTE) comprises deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT occurs at an incidence of 1/1,000 and risk factors include immobilization, hospitalization, surgery, thrombophilia and positive family history, cancer, pregnancy, and other hormonal effects. Commonly, clinical signs and symptoms for DVT are unreliable, especially in hospitalized patients, but the clinical assessment of the pretest probability, for example, with the Wells score, is an important component in the diagnostic algorithm, where compression ultrasound also plays a central role. Treatment of DVT aims to acutely prevent PE and short-term and long-term VTE recurrence and to avoid the lon…

Aspirinmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentStandard treatmentDeep veinCompression stockingsmedicine.diseaseThrombophiliaThrombosisPulmonary embolismSurgeryPre- and post-test probabilitymedicine.anatomical_structuremedicinecardiovascular diseasesbusinessmedicine.drug
researchProduct

Correlation between IgA tissue transglutaminase antibody ratio and histological finding in celiac disease.

2011

OBJECTIVES: Positivity of both immunoglobulin A anti-tissue transglutaminase (TTG) and anti-endomysium antibodies (EMA) has a positive predictive value of nearly 100% for celiac disease (CD). The objective of the present study was to evaluate whether patients of any age, with high pretest probability of CD and high titre of anti-TTG and EMA positivity, have a high probability of intestinal damage and may not require the biopsy for final diagnosis. METHODS: A retrospective analysis of 412 consecutively referred patients, age range 10 months to 72 years, who underwent small-bowel biopsy for suspicion of CD and positivity to both anti-TTG and EMA, was performed at 4 Italian centers. Biopsies w…

Immunoglobulin AAdultMalemedicine.medical_specialtyPathologyAdolescentTissue transglutaminaseDuodenumBiopsySettore MED/08 - Anatomia PatologicaGastroenterologySeverity of Illness IndexCoeliac diseaseStatistics NonparametricYoung AdultCoeliac disease Transglutaminase antibodyGTP-Binding ProteinsPredictive Value of TestsInternal medicineSeverity of illnessBiopsymedicineHumansProtein Glutamine gamma Glutamyltransferase 2ChildAgedRetrospective StudiesSettore MED/12 - GastroenterologiaTransglutaminasesbiologymedicine.diagnostic_testbusiness.industryMusclesGastroenterologyInfantRetrospective cohort studyMiddle Agedmedicine.diseaseImmunoglobulin APre- and post-test probabilityCeliac DiseaseLogistic ModelsPredictive value of testsChild PreschoolPediatrics Perinatology and Child Healthbiology.proteinFemalebusinessJournal of pediatric gastroenterology and nutrition
researchProduct

Validation of STA-Liatest D-Di assay for exclusion of pulmonary embolism according to the latest Clinical and Laboratory Standard Institute/Food and …

2017

: Combined clinical pretest probability (PTP) and D-dimer testing have great diagnostic value for pulmonary embolism exclusion. To harmonize performance levels of D-dimer assays available on the market, the Clinical and Laboratory Standard Institute (CLSI) has published a guideline, endorsed by the US Food and Drug Administration (FDA). Such guideline specifies the ideal D-dimer assay characteristic and target population. This study was conducted following the CLSI guideline to upgrade the assay-intended use and obtain FDA clearance of STA-Liatest D-Di assay for pulmonary embolism exclusion in patient with low/moderate PTP. This was an international, multicenter, prospective nonrandomized, …

MalePediatricsmedicine.medical_specialtypulmonary embolism030204 cardiovascular system & hematologyFood and drug administrationFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicinemedicineHumans030212 general & internal medicineProspective StudiesSTA-Liatest D-Dibusiness.industryUnited States Food and Drug AdministrationClinical and Laboratory Standard InstituteFood and Drug AdministrationHematologyGeneral MedicineGuidelineOriginal ArticlesMiddle Agedmedicine.diseaseThrombosisConfidence intervalUnited StatesPulmonary embolismPre- and post-test probabilityD-dimerEmergency medicineAmbulatoryBiological AssayFemalebusinessVenous thromboembolismBlood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct

Becton Dickinson Directigen EZ Flu A+B assay in the diagnosis of pandemic influenza A H1N1 2009 virus infection in adult patients

2011

To the editor: The recent emergence and spread of the pandemic influenza A H1N1 2009 virus demands the evaluation of rapid antigen assays for their ability to detect this novel subtype of influenza A virus. Data on the ability of BD Directigen EZ Flu A+B immunochromatographic (IC) assay (Beckton Dickinson and Company, Sparks, MD, USA) to detect the pandemic influenza A virus strain in fresh clinical samples have been recently published. 1 , 2 , 3 , 4 , 5 In these studies, the majority of specimens were collected from pediatric patients, and the sensitivities reported ranged from 46·8% to 76·6%. As viral shedding in the upper respiratory tract during influenza virus infection is of greater m…

Pulmonary and Respiratory Medicinemedicine.diagnostic_testEpidemiologybusiness.industryPublic Health Environmental and Occupational HealthBecton dickinsonmedicine.disease_causeVirologyVirusPre- and post-test probabilityInfectious DiseasesImmunoassayPandemicInfluenza A virusMedicineInfection controlViral sheddingbusinessInfluenza and Other Respiratory Viruses
researchProduct

Diagnosis and Treatment of Lower Extremity Venous Thromboembolism

2020

Importance: Incidence rates for lower extremity deep vein thrombosis (DVT) range from 88 to 112 per 100 000 person-years and increase with age. Rates of recurrent VTE range from 20% to 36% during the 10 years after an initial event.Observations: PubMed and Cochrane databases were searched for English-language studies published from January 2015 through June 2020 for randomized clinical trials, meta-analyses, systematic reviews, and observational studies. Risk factors for venous thromboembolism (VTE), such as older age, malignancy (cumulative incidence of 7.4% after a median of 19 months), inflammatory disorders (VTE risk is 4.7% in patients with rheumatoid arthritis and 2.5% in those withou…

medicine.medical_specialtyVena Cava FiltersDeep vein01 natural sciencesPostthrombotic Syndromelaw.inventionFibrin Fibrinogen Degradation Products03 medical and health sciencesSex Factors0302 clinical medicineRandomized controlled trialPredictive Value of TestsRisk FactorslawInternal medicineMedical IllustrationFactor V LeidenHumansThrombophiliaMedicineCumulative incidencecardiovascular diseases030212 general & internal medicine0101 mathematicsLife StyleThrombectomyUltrasonographybusiness.industry010102 general mathematicsAge FactorsWarfarinVenous ThromboembolismGeneral Medicinemedicine.diseaseThrombosisPre- and post-test probabilitymedicine.anatomical_structureLower ExtremityPredictive value of testsWarfarinSymptom AssessmentbusinessBiomarkersFactor Xa Inhibitorsmedicine.drugJAMA
researchProduct